Earnings Summary

Myriad Genetics Inc.’s net profit fell -723.4% since last year same period to $-116.1Mn in the Q2 2023. On a quarterly growth basis, Myriad Genetics Inc. has generated -112.25% fall in its net profits since last 3-months.

Myriad Genetics Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.1 - a 32.79% jump from last quarter’s estimates.

Myriad Genetics Inc.’s earning per share (EPS) estimates for the current year stand at -0.1.

Myriad Genetics Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the Myriad Genetics Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Myriad Genetics Inc.’s return on assets (ROA) stands at -0.09.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Myriad Genetics Inc.’s return on equity (ROE) stands at -0.3.